Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose-escalation Study of Radio- Labeled Antibody, FF-21101(90Y) for the Treatment of Advanced Cancer

NCT02454010 is registered in ClinicalTrials.gov with Fujifilm Pharmaceuticals U.S.A., Inc. as lead sponsor.

NCT NCT02454010
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02454010 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose-escalation Study of Radio- Labeled Antibody, FF-21101(90Y) for the Treatment of Advanced Cancer
Lead sponsor
Fujifilm Pharmaceuticals U.S.A., Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2016
Completion date
October 31, 2021
Enrollment
73 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor